Entrada closes $224M upfront Vertex collaboration for DM1; cash runway to H2 2025

Entrada Therapeutics, Inc.

Closed global collaboration with Vertex for ENTR-701 and other DM1 research; Vertex leads development.
Received $224M upfront plus $26M equity investment at $16.26 per share (1,618,613 shares).
Eligible for up to $485M in research, development, regulatory, and commercial milestones.
Entitled to tiered royalties on future net sales of any products from the collaboration.
Proceeds extend cash runway into second half of 2025, funding DMD and other EEV programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.